Research Article
Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer
Table 2
Univariate and multivariate analyses of overall survival.
| | Characteristic | Univariate analysis | Multivariate analysis | | HR (95% CI) | value | HR (95% CI) | value |
| | Age | ≤60/>60 | 1.245 (0.625–2.856) | 0.156 | | | | Sex | Female/male | 0.653 (0.302–1.127) | 0.129 | | | | Tumor site | Head/body/tail | 0.936 (0.648–1.582) | 0.832 | | | | Tumor size (cm) | ≤5/>5 | 1.925 (1.056, 3.559) | 0.046 | 1.369 (0.625, 2.848) | 0.521 | | Tumor volume (cm3) | ≤37/>37 | 2.486 (1.245–4.325) | 0.009 | 2.675 (1.230–7.215) | 0.035 | | Local recurrence | ≤6 mo/>6 mo | 3.522 (1.362–7.023) | 0.006 | 0.542 (0.308–2.034) | 0.384 | | WBC (×109) | ≤10/>10 | 1.352 (0.475–2.322) | 0.789 | | | | HGB (g/L) | ≤120/>120 | 1.086 (0.365–1.458) | 0.426 | | | | PLT (× 109) | ≤300/>300 | 1.335 (0.468–3.589) | 0.459 | | | | ALT (U/L) | ≤40/>40 | 0.895 (0.257–1.752) | 0.658 | | | | AST (U/L) | ≤40/>40 | 0.235 (0.128–1.329) | 0.457 | | | | ALP (U/L) | ≤100/>100 | 0.965 (0.042–1.436) | 0.689 | | | | CA19-9 level | ≤35/>35 | 1.350 (0.618–3.572) | 0.245 | | | | Complications | Yes/no | 0.621 (0.321–1.126) | 0.096 | | | | IRE | With/without GEM | 0.389 (0.178–0.952) | 0.045 | 0.422 (0.157–0.958) | 0.007 |
|
|
IRE: irreversible electroporation; GEM: gemcitabine; HR: hazard ratio; WBC: white blood cell count; HGB: hemoglobin; PLT: platelet count; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; CA19-9: carbohydrate antigen 19-9.
|
